MedicQuant is an Aarhus based medtech startup that is revolutionizing patient care by developing a tool that measures drug levels at the point of care. This provides clinicians with the crucial information they need for rapid and life-saving management of patients. MedicQuant’s first solution focuses on anticoagulation therapy for acute stroke patients. By providing insight into this therapy, clinicians can determine the correct life-saving management of stroke patients, greatly improving time to treatment and reducing mortality and disability.

Love Fuel assess you and your partner's personality, to recommend Acts of Love, either traditional or surprising with a twist. At our core, we are a team of researchers building a product at the intersection of AI and Psychology, with close ties to large universities in Denmark. We do not focus on overly romantic non-sense, we understand users want personalized real acts and not just "unrealistic romantic acts".  

🚀 About Halfspace.ai: Welcome to Halfspace.ai, where our mission is to revolutionise the world of data by building next-generation artificial intelligence products. Our team of experts create state-of-the-art AI solutions that transform businesses, improve lives, and shape the future. We take pride in our diverse and inclusive work environment that fosters creativity, collaboration, and continuous learning.

Our mission is to solve easy EV charging across the Nordics. One app to find the best route, charging stops based on your preferences, charge at any operator, and get smart suggestions based on your behaviour. We seek to be at the forefront of EV technology. At the charger, in the car, and at home. Join us in becoming the #1 EV app!

Unseen Bio™ was founded in 2018 with a vision to increase awareness of the importance of gut health as a means of preventing disease. Our mission is to strengthen the microbiome in order to improve the biodiversity crisis in the gut. Based on a thorough analysis of the microbiome, we provide personal dietary recommendations aimed at increasing biodiversity and improving gut health for the individual. Based on the latest knowledge in the microbiome area and with a focus on preventive healthcare, we are constantly developing our digital platform for intestinal health Digital Gut™.

Motionshift is the next generation online easy-to-use video and ad editor with customizable templates, footage, 2D & 3D assets ⭐. At Motionshift we empower marketers, social media managers, designers and creators to make 2D and photo-realistic 3D animated videos for social content, commercials, websites in a simple way, while making it easier to collaborate across marketing teams. We're a very small team achieving big results fast. As one of our first team members, you would be joining a team that encourages and values your contribution, creativity, and drive to do better every day. We are creating a new paradigm for 3D video creation, join us!

kicker.cloud provides end-to-end project management software for complex projects, such as M&A and private investments. Covering target tracking, project execution, and value creation / integration, the platform helps users improve efficiency, reduce operational risk, and drive scalable operations within organisations. All data is integrated, allowing companies to take their data re-usage, automation, and analytics to the next level for enhanced insights and decision making. The solution is looking to revolutionise the finance sector, with applications and ambitions far beyond.

Founded in 2018 by Bård Anders and Stig Olav Kasin, PortalOne is the world’s first hybrid games platform. Hybrid games are a new category of entertainment that seamlessly mix games with live shows that are embedded directly inside the games. This mobile-first content gives users a more engaging games experience, with stunning visuals and enhanced interactivity while allowing users to compete for prizes. We enrich everyday life by providing captivating, positive entertainment — with rewarding interactions that transform virtual wins into real-world rewards. PortalOne is US-based with a subsidiary in Oslo, Norway Hybrid Games are a whole new category of unique gaming entertainment. We harness the power of the Unreal Engine and other technologies to create unique content with stunning visuals and interactivity.We have global financial backing and global partners.

SonoClear AS develops an acoustic contrast fluid to remove noise in ultrasound images, used during brain tumor surgery to guide tumor removal. The goal is to be sure that all tumor is removed, as total resection improves patient outcomes. The technology is developed by neurosurgeons at St.Olavs hospital and engineers at Sintef. The technology is patented worldwide and is developed as a medical device according to ISO13485. The core team consists of CTO, Medical advisor, Quality manager, and Regulatory officer. SonoClear plan for market access in USA and EU in 4q20 and 4q21, respectively.

Klarna offer smoooth payments to 130.000 webshops and retailers across the globe. The company has 2500 employees spread over our 14 markets. Klarna Checkout is the main product, which offers merchants 1 integration, 1 agreement, 1 settlement for handling payments online and in stores. Klarna Norway AS has 15 (and increasing) employees who work at the 26th floor at Posthuset in Oslo.

Estro has developed a patented solution to improve Fish Health for Norwegian and International Fish farms, the "SeaNest" solution reduce mortality, and facilitate and improve the working environment for both farmer and Fish. A controllable solution for the clean Fish in the Battle against the lice, zero contamination, and no loose parts eliminate the risk of pollution. Easy to Wash and handle. We have signed a full-scale test program with some of the largest companies within the business, and so far with a positive result. First Emission fulfilled mid of 2018, and the commercialization process started.

In early 2021, we began exploring eye-tracking technology. We discovered its enormous potential when combined with in-game statistics and data analytics. The esports industry is becoming increasingly data-driven and professionalized. Teams are more focused on sustainable and healthy gaming routines. We can help them improve their skills and take care of eye health, sleep, and more.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Qlerify is an AI-powered collaborative software modeling platform helping transformation teams to digitalize enterprise business processes very fast - up to 100X faster compared to current practices. Our platform swiftly identifies business workflows and transforms them into comprehensive technical system blueprints for engineers—achieving what usually takes months, in days. Moreover, our platform is capable of constructing significant segments of the codebase for business applications with AI. Our solution combines several powerful agile collaboration tools with a selection of Large Language Models (LLM), including a finetuned LLM trained on our proprietary business process datasets. The collaboration features of Qlerify brings people together across silos and unites the perspectives of all stake holders. You get one dedicated place to identify and refine processes, features and data where you can visualise, structure, collaborate, and keep track of questions and conversations. With Qlerify, ordinary users can rapidly turn their domain knowledge into visual blueprints in a format that developers love and can use instantly to create better software faster.